New drug shows promise for rare hormone disorder
NCT ID NCT03257462
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a new drug called SPR001 in 24 adults with classic congenital adrenal hyperplasia (CAH), a genetic condition that disrupts hormone production. The study aimed to see if SPR001 is safe and can improve hormone control. Participants took multiple doses of the drug, and researchers measured changes in key hormones like 17-hydroxyprogesterone. The results could point toward a better way to manage this lifelong condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SPR001 capsules
What this could lead to
If successful, SPR001 could offer a new way to better control hormone levels in people with classic congenital adrenal hyperplasia, potentially reducing symptoms and the need for high-dose steroids.
What could go wrong
This is a small, early-phase trial with only 24 participants. The drug may not show enough benefit or could have side effects. More research is needed before it could become a treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL ADRENAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Spruce Biosciences Clinical Site
Orange, California, 92123, United States
-
Spruce Biosciences Clinical Site
San Diego, California, 92123, United States
-
Spruce Biosciences Clinical Site
Melbourne, Florida, 32935, United States
-
Spruce Biosciences Clinical Site
Atlanta, Georgia, 30046, United States
-
Spruce Biosciences Clinical Site
Indianapolis, Indiana, 46202, United States
-
Spruce Biosciences Clinical Site
Ann Arbor, Michigan, 48109, United States
-
Spruce Biosciences Clinical Site
Minneapolis, Minnesota, 55414, United States
-
Spruce Biosciences Clinical Site
Las Vegas, Nevada, 89148, United States
-
Spruce Biosciences Clinical Site
Philadelphia, Pennsylvania, 19104, United States